Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection

OBJECTIVE: To determine the durability over 96 weeks of safety and efficacy of lopinavir/ritonavir (LPV/r) and raltegravir (RAL) which was demonstrated to have non-inferior efficacy relative to a regimen of LPV/r with nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTIs) (Control) in pri...

Descripción completa

Detalles Bibliográficos
Autores principales: Amin, Janaki, Boyd, Mark A., Kumarasamy, Nagalingeswaran, Moore, Cecilia L., Losso, Marcello H., Nwizu, Chidi A., Mohapi, Lerato, Kerr, Stephen J., Sohn, Annette H., Teppler, Hedy, Renjifo, Boris, Molina, Jean-Michel, Emery, Sean, Cooper, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4344344/
https://www.ncbi.nlm.nih.gov/pubmed/25723472
http://dx.doi.org/10.1371/journal.pone.0118228

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4344344/
https://www.ncbi.nlm.nih.gov/pubmed/25723472
http://dx.doi.org/10.1371/journal.pone.0118228

Ejemplares similares